

CARDIOLOGY III PANEL

EDITORIAL BOARD LIAISON

Judy W.M. Cheng, Pharm.D., MPH,
FCCP, BCPS (AQ Cardiology)
Professor of Pharmacy Practice
Department of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacist
Department of Pharmacy
Brigham and Women's Hospital
Boston, Massachusetts

CARDIOVASCULAR DISEASE IN WOMEN

Author

Shannon W. Finks, Pharm.D., BCPS (AQ Cardiology)
Associate Professor
Department of Clinical Pharmacy
University of Tennessee College of Pharmacy
Clinical Pharmacy Specialist, Cardiology
Department of Pharmacy
VA Medical Center
Memphis, Tennessee

Reviewers

Anne L. Hume, Pharm.D., FCCP, BCPS
Professor of Pharmacy
Department of Pharmacy Practice
University of Rhode Island
Kingston, Rhode Island
Adjunct Professor of Family Medicine
Alpert School of Medicine at Brown University
Providence, Rhode Island

Anne P. Spencer, Pharm.D., FCCP,
BCPS (AQ Cardiology)
Cardiovascular Care Pharmacy Specialist
Roper Hospital
Roper Saint Francis Healthcare
Charleston, South Carolina

ANTICOAGULATION MANAGEMENT IN PREGNANCY

Authors

Nathan P. Clark, Pharm.D., BCPS, CACP
Clinical Pharmacy Supervisor
Anticoagulation Service
Kaiser Permanente Colorado
Clinical Assistant Professor
University of Colorado Denver School of Pharmacy
Aurora, Colorado

Mary Beth Dowd, Pharm.D., BCPS, CACP
Clinical Pharmacy Supervisor
Cardiac Risk Service
Kaiser Permanente Colorado
Aurora, Colorado

Reviewers

Amy M. Franks, Pharm.D.
Associate Professor
Department of Pharmacy Practice
University of Arkansas for Medical
Sciences College of Pharmacy
Little Rock, Arkansas

Mindi S. Miller, Pharm.D., BCPS
Clinical Associate Professor
Department of Clinical and Administrative Pharmacy
University of Georgia College of Pharmacy
Athens, Georgia
Clinical Pharmacist
Emory Healthcare
Atlanta, Georgia

Michelle M. Richardson, Pharm.D., FCCP, BCPS (Chair)
Special and Scientific Staff
William B. Schwartz Division of Nephrology
Tufts Medical Center
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, Massachusetts

EVALUATING DRUG-INDUCED CVD: A PHARMACOEPIDEMIOLOGIC PERSPECTIVE

Authors

Brian J. Quilliam, Ph.D., R.Ph.
Associate Professor of Pharmacoepidemiology
Department of Pharmacy Practice
University of Rhode Island, College of Pharmacy
Kingston, Rhode Island

Marilyn M. Barbour, Pharm.D., FCCP, BCPS
Professor of Pharmacy
Department of Pharmacy Practice
University of Rhode Island
Kingston, Rhode Island
Adjunct Associate Professor of Medicine
Alpert School of Medicine at Brown University
Providence, Rhode Island

Reviewers

Cynthia Jackevicius, Pharm.D., M.Sc.,
FCSHP, BCPS (AQ Cardiology)
Associate Professor of Pharmacy Practice
College of Pharmacy, Western University
Pomona, California
Clinical Pharmacy Specialist, Cardiology
VA West Los Angeles Healthcare Center
Los Angeles, California
Adjunct Scientist
Institute for Clinical Evaluative Sciences
Toronto, Ontario, Canada

Judy W.M. Cheng, Pharm.D., MPH,
FCCP, BCPS (AQ Cardiology)
Professor of Pharmacy Practice
Department of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacist
Department of Pharmacy
Brigham and Women's Hospital
Boston, Massachusetts

STATISTICS: STUDY DESIGN IN RECENT CARDIOLOGY TRIALS

Authors

Ross T. Tsuyuki, Pharm.D., BSPharm
M.Sc., FCSHP, FACC
Professor of Medicine (Cardiology)
Director, EPICORE Centre/COMPRIS
Department of Medicine
Faculty of Medicine and Dentistry
University of Alberta
Edmonton, Alberta, Canada

Sipi Garg, M.Sc.
University of Alberta, EPICORE Centre
Edmonton, Alberta, Canada

Reviewers

Kai I. Cheang, Pharm.D., M.Sc., FCCP, BCPS
Associate Professor
Department of Pharmacy
Virginia Commonwealth University
Richmond, Virginia

Marianne McCollum, Ph.D., BSPharm, BCPS
Assistant Dean for Assessment
School of Pharmacy
Rueckert-Hartman College for Health Professions
Regis University
Denver, Colorado

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 1, Cardiology III chapters:

Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP
Oncology Clinical Pharmacy Specialist
Park Nicollet Health Services Methodist Hospital
Minneapolis, Minnesota

Mary C. Gurnee, Pharm.D.
Pharmacist Consultant
Overland Park, Kansas

Mary Lee, Pharm.D., FCCP, BCPS
Vice President and Chief Academic Officer
Pharmacy and Health Sciences Education
Midwestern University
Professor of Pharmacy Practice
Midwestern University
Chicago College of Pharmacy
Downers Grove, Illinois

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Marilyn M. Barbour (New England Research Institute); Steven A. Baroletti (Sanofi-aventis); Michael A. Crouch (ARCA biopharma); Paul Dobesh (Sanofi-aventis, Eli Lilly, Inc., CV Therapeutics); Michael Dorsch (Merck); Shannon Willhite Finks (Novartis Pharmaceuticals); Jeremy D. Flynn (The Medicines Co., Novo Nordisk); Brian A. Hemstreet (Conexus Health); Lisa C. Hutchison (Arkansas Medicaid); Heath R. Jennings (American Heart Association); Lynette Moser (Michigan Department of Community Health); Kerry K. Pickworth (The Medicines Co., Merck, ARCA biopharma); Brian J. Quilliam (Ortho-McNeil Janssen); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, *Annals of Pharmacotherapy*); Jeffrey T. Sherer (Sturge-Weber Foundation); Evan Sisson (American Association of Diabetes Educators, University of Pittsburgh School of Pharmacy, Novartis Pharmaceuticals); Anne P. Spencer (ARCA biopharma); Sarah A. Spinler (Xcenda, Sanofi-aventis); Zachary A. Stacy (Sanofi-aventis, CV Therapeutics)

Stock Ownership: Katherine H. Chessman (Procter & Gamble [stock owned by spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Emilie Karpiuk (Cardinal Health); Michelle Richardson (TEI Biosciences [stock owned by spouse or significant other])

Royalties: Lisa C. Hutchison (ASHP)

Grants: Kai I. Cheang (NIH NICHD); Judy W.M. Cheng (St. Jude's Medical Research Center); Nathan Clark (Sanofi-aventis); Amy M. Franks (Pfizer); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Cynthia Jackevicius (ACCP, CIHR [two grants]); Brian J. Quilliam (Takeda Pharmaceuticals North America); Michelle Richardson (NIH NIDDK [two grants]); Nancy L. Shapiro (University of Illinois – Chicago Vahlteich Award); Anne P. Spencer (Pfizer)

Honoraria: Nathan Clark (McMaster University, University of New Mexico, University of Colorado School of Pharmacy); Michael A. Crouch (The Medicines Co., Ortho-McNeil), Paul Dobesh (Sanofi-aventis); Michael Dorsch (Sanofi-aventis); Jeremy D. Flynn (The Medicines Co.); Kerry K. Pickworth (The Medicines Co.); Michelle Richardson (Amgen); Evan Sisson (Novartis Pharmaceuticals); Sarah A. Spinler (Sanofi-aventis, GlaxoSmithKline); Zachary A. Stacy (Sanofi-aventis)

Nothing to Disclose: Adam J. Bursua, Benita Busch, Clarence Chant, Terri S. Cook, William E. Dager, Mary Beth Dowd, Sipi Garg, Kevin W. Hatton, Matthew K. Ito, Marianne McCollum, Mindi S. Miller, Kari L. Olson, Cynthia A. Sanoski, Ross T. Tsuyuki, Benjamin W. Van Tassell, Daniel M. Witt

ROLE OF ACCP: ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmaceutical Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

ROLE OF BPS: The Board of Pharmaceutical Specialties is an autonomous certification agency of the American Pharmacists Association. BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm. Other questions regarding recertification should be directed to:

Board of Pharmaceutical Specialties
2215 Constitution Avenue, NW
Washington, DC 20037
(202) 429-7591
www.bpsweb.org